Altre lingue Dimerix Limited

Azioni

DXB

AU000000DXB7

Mercato chiuso - Australian S.E. Altri mercati azionari 08:10:11 03/05/2024			Variaz. 5gg	Var. 1 gen.
0,36 ^AUD	+7,46%		+12,50%	+75,61%

01/05	Dimerix ottiene l'approvazione del piano pediatrico nel Regno Unito per il farmaco per le malattie renali	MT
19/04	DIMERIX LIMITED : Euroz Hartleys ancora positivo	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Dimerix Secures Pediatric Plan Approval in the UK for Kidney Disease Medication	01/05
Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter	22/04
Dimerix Raises AU$20 Million for Kidney Disease Study	12/03
Dimerix Expanding Kidney Drug Study After DMX-200 Performs Better than Placebo	11/03
Dimerix Limited Reports Earnings Results for the Half Year Ended December 31, 2023	25/02
Dimerix Limited Announces Appointment of Mark Diamond as Director	01/12
Dimerix Secures Investigational New Drug Approval for Kidney Disease Medication in China; Shares Rally 11%	28/11
Dimerix Appoints Nonexecutive Chair	20/11
Dimerix Receives AU$10.7 Million Upfront Payment for Commercialization Rights	07/11
Dimerix Appoints Medical Chief	23/10/23
Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer	22/10/23
ADVANZ PHARMA and Dimerix enter into an Exclusive License Agreement to commercialise DMX-200 in Europe, Canada, Australia, and New Zealand	05/10/23
Softer US Employment Data End Australian Shares' Three-Day Losing Streak	05/10/23
Dimerix Surges 154% After Securing License Deal for Kidney Disease Drug	05/10/23
Dimerix Secures Conditional US FDA Clearance for Kidney Medication Brand Name	25/09/23
Dimerix Secures Regulatory Nod to Conduct Kidney Disease Drug Trial in Malaysia	22/09/23
Dimerix Secures AU$9 Million R&D Tax Rebate; Shares Rise 3%	13/09/23
Dimerix Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/08/23
Dimerix Secures Approval for Pediatric Kidney Disease Plan in Europe	05/07/23
Dimerix Secures Study Design Approval in China for Phase Three Kidney Disease Trial; Shares Rise 6%	03/07/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Dimerix Limited

Azioni

DXB

AU000000DXB7

Altre lingue

Filtri